表紙
市場調査レポート

ウイルス性結膜炎治療薬の世界市場:2016年〜2020年

Global Viral Conjunctivitis Drugs Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 354379
出版日 ページ情報 英文 53 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
ウイルス性結膜炎治療薬の世界市場:2016年〜2020年 Global Viral Conjunctivitis Drugs Market 2016-2020
出版日: 2016年03月03日 ページ情報: 英文 53 Pages
概要

世界のウイルス性結膜炎治療薬の市場は2016年から2020年にかけて2.41%のCAGR (複合年間成長率) で拡大することが予測されています。

当レポートでは、世界のウイルス性結膜炎治療薬の市場を調査し、市場および製品の概要、主要ベンダーの提供製品、疾患の概要、パイプラインの動向、市場全体および投薬経路・地域別の市場規模の推移と予測、市場への影響因子の分析、主な動向、主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 調査範囲

  • 市場概要
  • 主要ベンダーの製品

第3章 市場調査手法

  • 調査手法
  • 経済指標

第4章 イントロダクション

  • 主な市場ハイライト

第5章 疾患の概要

  • 結膜炎
  • ウイルス性結膜炎
  • 兆候・症状
  • 診断
  • 管理
  • 疫学
  • 経済的負担

第6章 パイプライン分析

  • FST-100
  • APD-209点眼薬
  • SPL7013
  • EKC-Cide
  • PP-001

第7章 市場環境

  • 市場概要
  • 市場規模・予測
  • 米国のウイルス性結膜炎治療薬市場
  • ファイブフォース分析

第8章 市場分析:投薬経路別

  • 外用
  • 経口
  • 硝子体内

第9章 市場分析:地域別

  • 世界市場の推移と予測:地域別
  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋

第10章 市場成長因子

  • 意識の拡大
  • アンメットニーズ
  • 高い発症率

第11章 市場成長因子の影響

第12章 市場課題

  • 低い診断率
  • 副作用・低い有効性
  • 既存療法への満足
  • 代替療法のアベイラビリティ

第13章 成長因子と課題の影響

第14章 市場動向

  • 戦略的提携・M&A
  • オフラベル薬剤の利用
  • R&Dの活発化

第15章 ベンダー情勢

  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb
  • その他の有力ベンダー

第16章 付録

第17章 Technavioについて

目次
Product Code: IRTNTR8392

About Viral Conjunctivitis Drugs

Viral conjunctivitis, or pink eye, is a type of infectious conjunctivitis that is commonly caused by an adenovirus. Herpes simplex virus (HSV), picornavirus (enterovirus 70, Coxsackie A24), varicella-zoster virus, poxvirus (molluscum contagiosum and vaccinia), and human immunodeficiency virus (HIV) are some of the other viruses that are responsible for the infection. Discomfort through watery discharge is the main symptom of this highly contagious condition. It is often associated with keratoconjunctivitis, which results in slightly blurred vision. No specific treatment option is available for the infection, which heals by itself in 2-3 weeks. Antibiotics and anti-inflammatory drugs are used only if the condition persists. In certain instances, when the infection is serious or persists for weeks, topical antiviral drugs are used. Corneal lesions persist for months even after the condition heals.

Technavio's analysts forecast the global viral conjunctivitis drugs market to grow at a CAGR of 2.41% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global viral conjunctivitis drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of viral conjunctivitis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Viral Conjunctivitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb

Other Prominent Vendors

  • Adenovir Pharma
  • Marinomed Biotechnologie
  • Mediolanum Laboratoires
  • NanoViricides
  • Nicox
  • Novartis
  • Panoptes Pharma
  • Rapid Pathogen Screening
  • Shire
  • Starpharma
  • Valeant Pharmaceuticals

Market driver

  • Rising awareness
  • For a full, detailed list, view our report

Market challenge

  • Low diagnosis rate
  • For a full, detailed list, view our report

Market trend

  • Use of off-label drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Conjunctivitis
  • Viral conjunctivitis
  • Signs and symptoms
  • Diagnosis
  • Management
  • Epidemiology
  • Economic burden

PART 06: Pipeline analysis

  • FST-100
  • APD-209 eye drops
  • SPL7013
  • EKC-Cide
  • PP-001

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Viral conjunctivitis drugs market in US
  • Five forces analysis

PART 08: Market segmentation by route of administration

  • Topical
  • Oral
  • Intravitreal

PART 09: Geographical segmentation

  • Global viral conjunctivitis drugs market by geography 2015-2020
  • Viral conjunctivitis drugs market in Americas
  • Viral conjunctivitis drugs market in EMEA
  • Viral conjunctivitis drugs market in APAC

PART 10: Market drivers

  • Rising awareness
  • Unmet needs for viral conjunctivitis
  • High prevalence

PART 11: Impact of drivers

PART 12: Market challenges

  • Low diagnosis rate
  • Adverse effects and limited efficacy of drugs
  • Satisfaction with existing therapies
  • Availability of alternative therapies

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Strategic alliances and M&A
  • Use of off-label drugs
  • Rise in R&D

PART 15: Vendor landscape

  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

PART 17: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Types of conjunctivitis
  • Exhibit 03: Major types of viral conjunctivitis
  • Exhibit 04: Signs and symptoms of types of viral conjunctivitis
  • Exhibit 05: Diagnostic algorithm for viral conjunctivitis
  • Exhibit 06: Drugs used to treat conjunctivitis
  • Exhibit 07: Comparison of prevalent rates in different types of conjunctivitis among adults and pediatric population (%)
  • Exhibit 08: Global viral conjunctivitis drugs market: Pipeline portfolio
  • Exhibit 09: Global viral conjunctivitis drugs market 2015-2020 ($ millions)
  • Exhibit 10: Snapshot of global viral conjunctivitis drugs market
  • Exhibit 11: Percentage share of US in the global viral conjunctivitis drugs market 2015
  • Exhibit 12: Viral conjunctivitis drugs market in US 2015-2020 ($ millions)
  • Exhibit 13: Five forces analysis
  • Exhibit 14: Global viral conjunctivitis drugs market segment by route of administration
  • Exhibit 15: Global viral conjunctivitis drugs market by geography 2015
  • Exhibit 16: Viral conjunctivitis drugs market by geography 2015-2020 ($ millions)
  • Exhibit 17: Viral conjunctivitis drugs market in Americas 2015-2020 ($ millions)
  • Exhibit 18: Viral conjunctivitis drugs market in EMEA 2015-2020 ($ millions)
  • Exhibit 19: Viral conjunctivitis drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 20: Global viral conjunctivitis drugs market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 21: Impact of drivers
  • Exhibit 22: Impact of drivers and challenges
  • Exhibit 23: Akorn: YOY growth and revenue generated from ophthalmic segment 2011-2013 ($ millions)
  • Exhibit 24: Akorn: Key takeaways
  • Exhibit 25: Alcon: Business segmentation by revenue 2014
  • Exhibit 26: Alcon: YoY growth and revenue generated from sales of ophthalmic products 2011-2014 ($ billions)
  • Exhibit 27: Alcon: Key takeaways
  • Exhibit 28: Allergan: Key takeaways
  • Exhibit 29: Bausch & Lomb: Key takeaways
Back to Top